Compare TG Therapeutics Inc (TGTX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs ProShares UltraPro QQQ ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while ProShares UltraPro QQQ ETF trades at $81.28 (market cap $38.74B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 4.7× TG Therapeutics Inc's market cap, and ProShares UltraPro QQQ ETF is more actively traded (65,384,797 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| TGTX | TQQQ | |
|---|---|---|
Market Cap | $8.16B | $38.74B |
Volume | 1,735,121 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $87.22 |
52-Week Low | $26.94 | $37.89 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
TQQQ trades at $81.28, down 2.78% on the day, with technical indicators showing a bullish bias despite recent selling pressure. The ETF maintains a strong position near its pivot point of $81, supported by positive moving average signals. Recent news highlights ongoing institutional interest alongside concerns about hidden costs and volatility risks inherent in leveraged ETF structures.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face significant volatility risks amplified by the 3x leverage structure. Key opportunities include exposure to Nasdaq-100 growth, while risks center on expense ratios, financing costs, and potential market corrections that could magnify losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
